Acquisition of exclusive manufacturing and marketing rights for DOTATOC

- In-licensing of superior DOTA-Tyr3-octreotide

- Pharmaceutical development for treatment of NETs

- Excellent pharmacokinetic properties

ITM Isotope Technologies Munich AG (ITM) today announced that it has entered into an exclusive licensing agreement with Progenics Pharmaceuticals Inc. for pharmaceutical development and commercialization of radiolabeled DOTA-conjugated somatostatin analogue DOTA-[Tyr3]-octreotide (DOTATOC known as Edotreotide) for human oncology therapeutic use. Radiolabeled DOTATOC is a superior agent for safe and highly effective radionuclide therapy of somatostatin receptor positive tumors which offers excellent pharmacokinetic properties and highest affinity to somatostatin receptor subtypes 2 and 5.

Scope of license agreement

The sublicense granted by Progenics Pharmaceuticals Inc. covers exclusive worldwide manufacturing and marketing rights of DOTATOC and certain radiolabeled DOTATOC for human oncology therapeutic use except the countries Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Romania, Saudi Arabia, Syria, Turkey and United Arab Emirates. Further terms of the agreement were not disclosed.

Pharmaceutical development

ITM affiliate ITG Isotope Technologies Garching GmbH will develop radiolabeled DOTATOC for treatment of metastatic neuroendocrine tumors. In addition, DOTATOC as precursor is now available and will be distributed in GMP quality in cooperation with a leading supplier of advanced chemicals for nuclear medicine.


DOTATOC or Edotreotide is a superior synthetic somatostatin analog which binds perfectly to somatostatin receptors predominantly overexpressed in neuroendocrine tumors (NETs). NETs are rare kind of tumors which arise from neuroendocrine cells and may occur in different parts of the body.

DOTA-chelated peptide Edotreotide exhibits excellent pharmacokinetic properties and can be efficiently radiolabeled with medical radionuclides. Its excellent therapeutic properties have been successfully started in various clinical trials.

About ITM Isotope Technologies Munich AG

The itm Group is the leading company for the development, production and worldwide distribution of highly effective radionuclides for diagnosis and therapy as well as radionuclide-based medical devices. Its commitment to shaping the future of theranostics is built on robust platform technologies and innovative new generation radioisotopes which assure safety, performance and security of supply!


Christopher Morin
Manager Marketing & Corporate Communications
Phone: +49 89 289 13915
Mail: Christopher.Morin@itg-garching.de

Steffen Schuster
Phone: +49 89 289 13970
Mail : Steffen.Schuster@itm.ag

ITM Isotope Technologies Munich AG

Aufsichtsratsvorsitzender - Udo J. Vetter, Vorstandsvorsitzender - Steffen Schuster, Sitz der Gesellschaft - Lichtenbergstr. 1, 85748 Garching - HG M√ľnchen - HRB 154944